Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E STEPHENSON

Showing results (141-150 of 176) with videos related to

Pageof 18
Sort By:
Journal of Water and Health|September 27, 2023
Rapidly developed, optimized, and applied wastewater surveillance system for real-time monitoring of low-incidence, high-impact MPOX outbreakChandler H Wong, Zhihao Zhang, Walaa Eid, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Annals of Internal Medicine|February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus VaccineNadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
Cell Reports|December 16, 2020
HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral ReboundRasmus Offersen, Wen-Han Yu, Eileen P Scully, et al.
Nature|November 1, 2013
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeysDan H Barouch, James B Whitney, Brian Moldt, et al.
Nature Medicine|September 12, 2024
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trialBoris Julg, Victoria E K Walker-Sperling, Kshitij Wagh, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
Nature|November 15, 2016
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeysErica N Borducchi, Crystal Cabral, Kathryn E Stephenson, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Pageof 18

Showing results (141-150 of 176) with videos related to

Sort By:
Pageof 18
Journal of Water and Health|September 27, 2023
Rapidly developed, optimized, and applied wastewater surveillance system for real-time monitoring of low-incidence, high-impact MPOX outbreakChandler H Wong, Zhihao Zhang, Walaa Eid, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Annals of Internal Medicine|February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus VaccineNadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
Cell Reports|December 16, 2020
HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral ReboundRasmus Offersen, Wen-Han Yu, Eileen P Scully, et al.
Nature|November 1, 2013
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeysDan H Barouch, James B Whitney, Brian Moldt, et al.
Nature Medicine|September 12, 2024
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trialBoris Julg, Victoria E K Walker-Sperling, Kshitij Wagh, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
Nature|November 15, 2016
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeysErica N Borducchi, Crystal Cabral, Kathryn E Stephenson, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Pageof 18